1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet. 1896;1896:104-107, 162-165.
2. Lyons WR, Li CH, Johnson RE. The Hormonal Control of Mammary Growth and Lactation. Recent Progress in Hormone Research. 1958;14:219-254.
3. Nandi S. Endocrine Control of Mammary-Gland Development and Function in the C3h-He Crgl Mouse. Journal of the National Cancer Institute. 1958;21:1039-1063.
4. Sakakura T. Mammary Embryogenesis. In: Neville MC, Daniel CW, eds. The Mammary Gland: Development, regulation, and function. New York: Plenum Press; 1987:37-66.
5. Howard BA, Gusterson BA. Human breast development. J Mammary Gland Biol Neoplasia. 2000;5:119-37.
6. Wysolmerski JJ, Philbrick WM, Dunbar ME, Lanske B, Kronenberg H, Broadus AE. Rescue of the parathyroid hormone-related protein knockout mouse demonstrates that parathyroid hormone-related protein is essential for mammary gland development. Development. 1998;125:1285-94.
7. Mailleux AA, Spencer-Dene B, Dillon C, et al. Role of FGF10/FGFR2b signaling during mammary gland development in the mouse embryo. Development. 2002;129:53-60.
8. van Genderen C, Okamura RM, Farinas I, et al. Development of several organs that require inductive epithelial- mesenchymal interactions is impaired in LEF-1-deficient mice. Genes Dev. 1994;8:2691-703.
9. Garcia-Gasca A, Spyropoulos DD. Differential mammary morphogenesis along the anteroposterior axis in Hoxc6 gene targeted mice. Dev Dyn. 2000;219:261-76.
10. Phippard DJ, Weber-Hall SJ, Sharpe PT, et al. Regulation of Msx-1, Msx-2, Bmp-2 and Bmp-4 during foetal and postnatal mammary gland development. Development. 1996;122:2729-37.
11. Satokata I, Ma L, Ohshima H, et al. Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. Nat Genet. 2000;24:391-5. .
12. Wysolmerski JJ, Cormier S, Philbrick WM, et al. Absence of functional type 1 parathyroid hormone (PTH)/PTH-related protein receptors in humans is associated with abnormal breast development and tooth impaction. J Clin Endocrinol Metab. 2001;86:1788-94.
13. Sakakura T, Nishizuka Y, Dawe CJ. Mesenchyme-dependent morphogenesis and epithelium-specific cytodifferentiation in mouse mammary gland. Science. 1976;194:1439-41.
14. Russo J, Russo IH. Development of the human mammary gland. In: Neville MC, Daniel CW, eds. The Mammary Gland: Development, regulation, and function. New York: Plenum Press; 1987:67-93.
15. Vassilacopoulou D, Boylan ES. Mammary gland morphology and responsiveness to regulatory molecules following prenatal exposure to diethylstilbestrol. Teratog Carcinog Mutagen. 1993;13:59-74.
16. Rothschild TC, Boylan ES, Calhoon RE, Vonderhaar BK. Transplacental effects of diethylstilbestrol on mammary development and tumorigenesis in female ACI rats. Cancer Res. 1987;47:4508-16.
17. Boylan ES, Calhoon RE. Transplacental action of diethylstilbestrol on mammary carcinogenesis in female rats given one or two doses of 7,12-dimethylbenz(a)anthracene. Cancer Res. 1983;43:4879-84.
18. Wiesen JF, Young P, Werb Z, Cunha GR. Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. Development. 1999;126:335-44.
19. Daniel CW, Silberstein GB. Postnatal development of the rodent mammary gland. In: Neville MC, Daniel CW, eds. The Mammary Gland: Development, regulation, and function. New York: Plenum Press; 1987:3-36.
20. Flux DS. Growth of the mammary duct system in intact and ovariectomized mice of the CHI-strain. Journal of Endocrinology. 1954;11:223-237.
21. Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev. 1999;20:358-417.
22. Cunha GR, Young P, Hom YK, Cooke PS, Taylor JA, Lubahn DB. Elucidation of a role for stromal steroid hormone receptors in mammary gland growth and development using tissue recombinants. J Mammary Gland Biol Neoplasia. 1997;2:393-402.
23. Gallego MI, Binart N, Robinson GW, et al. Prolactin, growth hormone, and epidermal growth factor activate Stat5 in different compartments of mammary tissue and exert different and overlapping developmental effects. Dev Biol. 2001;229:163-75.
24. Kleinberg DL. Early mammary development: growth hormone and IGF-1. J Mammary Gland Biol Neoplasia. 1997;2:49-57.
25. Wood TL, Richert MM, Stull MA, Allar MA. The insulin-like growth factors (IGFs) and IGF binding proteins in postnatal development of murine mammary glands. J Mammary Gland Biol Neoplasia. 2000;5:31-42.
26. Hadsell DL, Bonnette SG. IGF and insulin action in the mammary gland: lessons from transgenic and knockout models. J Mammary Gland Biol Neoplasia. 2000;5:19-30.
27. Brisken C, Park S, Vass T, Lydon JP, O'Malley BW, Weinberg RA. A paracrine role for the epithelial progesterone receptor in mammary gland development. Proc Natl Acad Sci U S A. 1998;95:5076-81.
28. Ormandy CJ, Binart N, Kelly PA. Mammary gland development in prolactin receptor knockout mice. J Mammary Gland Biol Neoplasia. 1997;2:355-64.
29. Brisken C, Kaur S, Chavarria TE, et al. Prolactin controls mammary gland development via direct and indirect mechanisms. Dev Biol. 1999;210:96-106.
30. Cardiff RD, Wellings SR. The comparative pathology of human and mouse mammary glands. J Mammary Gland Biol Neoplasia. 1999;4:105-22.
31. Russo J, Santen RJ, Russo IM. Hormonal Control of Breast Development. In: Marshall JC, ed.
32. Lee PA, Xenakis T, Winer J, Matsenbaugh S. Puberty in girls: correlation of serum levels of gonadotropins, prolactin, androgens, estrogens, and progestins with physical changes. J Clin Endocrinol Metab. 1976;43:775-84.
33. Thorner MO, Round J, Jones A, et al. Serum prolactin and oestradiol levels at different stages of puberty. Clin Endocrinol (Oxf). 1977;7:463-8.
34. Ankarberg-Lindgren C, Elfving M, Wikland KA, Norjavaara E. Nocturnal application of transdermal estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous puberty in girls. J Clin Endocrinol Metab. 2001;86:3039-44.
35. Bartow SA. Use of the autopsy to study ontogeny and expression of the estrogen receptor gene in human breast. J Mammary Gland Biol Neoplasia. 1998;3:37-48.
36. Rose SR, Municchi G, Barnes KM, et al. Spontaneous growth hormone secretion increases during puberty in normal girls and boys. J Clin Endocrinol Metab. 1991;73:428-35.
37. Cullen KJ, Allison A, Martire I, Ellis M, Singer C. Insulin-like growth factor expression in breast cancer epithelium and stroma. Breast Cancer Res Treat. 1992;22:21-9.
38. Humphreys RC, Lydon JP, O'Malley BW, Rosen JM. Use of PRKO mice to study the role of progesterone in mammary gland development. J Mammary Gland Biol Neoplasia. 1997;2:343-54.
39. Russo J, Ao X, Grill C, Russo IH. Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat. 1999;53:217-27.
40. Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res. 1997;57:4987-91.
41. Lydon JP, Sivaraman L, Conneely OM. A reappraisal of progesterone action in the mammary gland. Journal of Mammary Gland Biology and Neoplasia. 2000;5:325-338.
42. Neville MC, Morton J, Umemura S. Lactogenesis. The transition from pregnancy to lactation. Pediatr Clin North Am. 2001;48:35-52.
43. Hartmann PE. Changes in the composition and yield of the mammary secretion of cows during the initiation of lactation. J Endocrinol. 1973;59:231-47.
44. Martin RH, Glass MR, Chapman C, Wilson GD, Woods KL. Human alpha-lactalbumin and hormonal factors in pregnancy and lactation. Clin Endocrinol (Oxf). 1980;13:223-30.
45. Flint DJ, Vernon RG. Effects of food restriction on the responses of the mammary gland and adipose tissue to prolactin and growth hormone in the lactating rat. J Endocrinol. 1998;156:299-305.
46. Benedek-Jaszmann LJ, Sternthal V. Late suppression of lactation with bromocriptine. Practitioner. 1976;216:450-4.
47. Forsyth IA. Comparative aspects of placental lactogens: structure and function. Exp Clin Endocrinol. 1994;102:244-51.
48. Nielsen PV, Pedersen H, Kampmann EM. Absence of human placental lactogen in an otherwise uneventful pregnancy. Am J Obstet Gynecol. 1979;135:322-6.
49. Gaede P, Trolle D, Pedersen H. Extremely low placental lactogen hormone (hPL) values in an otherwise uneventful pregnancy preceding delivery of a normal baby. Acta Obstet Gynecol Scand. 1978;57:203-9.
50. Bauman DE, Vernon RG. Effects of exogenous bovine somatotropin on lactation. Annu Rev Nutr. 1993;13:437-61.
51. Zhou Y, Xu BC, Maheshwari HG, et al. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc Natl Acad Sci U S A. 1997;94:13215-20.
52. Rimoin DL, Holzman GB, Merimee TJ, et al. Lactation in the absence of human growth hormone. J Clin Endocrinol Metab. 1968;28:1183-8.
53. Rosenbloom AL, Guevara-Aguirre J, Rosenfeld RG, Francke U. Growth hormone receptor deficiency in Ecuador. J Clin Endocrinol Metab. 1999;84:4436-43.
54. Deis RP, Delouis C. Lactogenesis induced by ovariectomy in pregnant rats and its regulation by oestrogen and progesterone. J Steroid Biochem. 1983;18:687-90.
55. Haslam SZ, Shyamala G. Progesterone receptors in normal mammary gland: receptor modulations in relation to differentiation. J Cell Biol. 1980;86:730-7.
56. Kalkwarf HJ. Hormonal and dietary regulation of changes in bone density during lactation and after weaning in women. J Mammary Gland Biol Neoplasia. 1999;4:319-29.
57. Capuco AV, Kahl S, Jack LJ, Bishop JO, Wallace H. Prolactin and growth hormone stimulation of lactation in mice requires thyroid hormones. Proc Soc Exp Biol Med. 1999;221:345-51.
58. Iwatani Y, Amino N, Tanizawa O, et al. Decrease of free thyroxin in serum of lactating women. Clin Chem. 1987;33:1217-9.
59. Butte NF, Hopkinson JM, Mehta N, Moon JK, Smith EO. Adjustments in energy expenditure and substrate utilization during late pregnancy and lactation. Am J Clin Nutr. 1999;69:299-307.
60. Neville MC, Sawicki VS, Hay WW, Jr. Effects of fasting, elevated plasma glucose and plasma insulin concentrations on milk secretion in women. J Endocrinol. 1993;139:165-73.
61. Crowley WR, Armstrong WE. Neurochemical regulation of oxytocin secretion in lactation. Endocr Rev. 1992;13:33-65.
62. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001;81:629-83.
63. McNeilly AS, Robinson IC, Houston MJ, Howie PW. Release of oxytocin and prolactin in response to suckling. Br Med J (Clin Res Ed). 1983;286:257-9.
64. Ueda T, Yokoyama Y, Irahara M, Aono T. Influence of psychological stress on suckling-induced pulsatile oxytocin release. Obstet Gynecol. 1994;84:259-62.
65. Subramanian MG. Alcohol inhibits suckling-induced oxytocin release in the lactating rat. Alcohol. 1999;19:51-5.
66. Haldar J, Hoffman DL, Zimmerman EA. Morphine, beta-endorphin and [D-Ala2] Met-enkephalin inhibit oxytocin release by acetylcholine and suckling. Peptides. 1982;3:663-8.
67. Young WS, 3rd, Shepard E, DeVries AC, et al. Targeted reduction of oxytocin expression provides insights into its physiological roles. Adv Exp Med Biol. 1998;449:231-40.
68. Widstrom AM, Winberg J, Werner S, Hamberger B, Eneroth P, Uvnas-Moberg K. Suckling in lactating women stimulates the secretion of insulin and prolactin without concomitant effects on gastrin, growth hormone, calcitonin, vasopressin or catecholamines. Early Hum Dev. 1984;10:115-22.
69. Battin DA, Marrs RP, Fleiss PM, Mishell DR, Jr. Effect of suckling on serum prolactin, luteinizing hormone, follicle- stimulating hormone, and estradiol during prolonged lactation. Obstet Gynecol. 1985;65:785-8.
70. Kvist Poulsen H, Rasmussen P, Riber Petersen M, Moller Pedersen S. Puerperal lactation inhibition with a novel 8 alpha-aminoergoline (CU 32-085). Gynecol Obstet Invest. 1984;17:139-44.
71. Wilde CJ, Knight CH, Flint DJ. Control of milk secretion and apoptosis during mammary involution. J Mammary Gland Biol Neoplasia. 1999;4:129-36.
72. Marti A, Feng Z, Altermatt HJ, Jaggi R. Milk accumulation triggers apoptosis of mammary epithelial cells. Eur J Cell Biol. 1997;73:158-65.
73. Kobielak K, Kobielak A, Roszkiewicz J, Wierzba J, Limon J, Trzeciak WH. Mutations in the EDA gene in three unrelated families reveal no apparent correlation between phenotype and genotype in the patients with an X-linked anhidrotic ectodermal dysplasia. Am J Med Genet. 2001;100:191-7.
74. Burck U, Held KR. Athelia in a female infant - heterozygous for anhidrotic ectodermal dysplasia. Clin Genet. 1981;19:117-21.
75. Taylor CD, Clugston PA. Breast reconstruction in ectodermal dysplasia. Ann Plast Surg. 1999;43:36-41.
76. Tuffli GA, Laxova R. Brief clinical report: new, autosomal dominant form of ectodermal dysplasia. Am J Med Genet. 1983;14:381-4.
77. Headon DJ, Overbeek PA. Involvement of a novel Tnf receptor homologue in hair follicle induction. Nat Genet. 1999;22:370-4.
78. Rosenberg CA, Derman GH, Grabb WC, Buda AJ. Hypomastia and mitral-valve prolapse. Evidence of a linked embryologic and mesenchymal dysplasia. N Engl J Med. 1983;309:1230-2.
79. Blackwell RE. Pathopysiology of the breast. In: Becker KL, ed. Principles and Practice of Endocrinology and Metabolism. Second Edition ed. Philadelphia: J.B. Lippincott; 1995.
80. Pierre ML, Jouglard JP. Treatment of unilateral congenital hypoplasia or absence of the breast. Plast Reconstr Surg. 1975;56:146-51.
81. Hollingsworth DR, Archer R. Massive virginal breast hypertrophy at puberty. Am J Dis Child. 1973;125:293-5.
82. Mehregan AH. Supernumerary nipple. A histologic study. J Cutan Pathol. 1981;8:96-104.
83. Urbani CE, Betti R. Accessory mammary tissue associated with congenital and hereditary nephrourinary malformations. Int J Dermatol. 1996;35:349-52.
84. Galli-Tsinopoulou A, Krohn C, Schmidt H. Familial polythelia over three generations with polymastia in the youngest girl. Eur J Pediatr. 2001;160:375-7.
85. Grossl NA. Supernumerary breast tissue: historical perspectives and clinical features. South Med J. 2000;93:29-32.
86. Frantz AG, Wilson JD. Endocrine disorders of the breast. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, eds. Williams Textbook of Endocrinology. 9 ed. Philadelphia: WB Saunders Co.; 1998.
87. Fisher W, Smith JW. Macromastia during puberty. Plast Reconstr Surg. 1971;47:445-51.
88. Lafreniere R, Temple W, Ketcham A. Gestational macromastia. Am J Surg. 1984;148:413-8.
89. Williams PC. Massive hypertrophy of the breasts and axillary breastsin successive pregnancies. American Journal of Obstetrics and Gynecology. 1957;74:1326-1329.
90. Burslem RW, Dewhurst CJ. Massive hypertrophy of the breasts in pregnancy. J Obstet Gyn Brit Em. 1952;59:380-381.
91. Khosla S, van Heerden JA, Gharib H, et al. Parathyroid hormone-related protein and hypercalcemia secondary to massive mammary hyperplasia. N Engl J Med. 1990;322:1157.
92. Finer N, Emery P, Hicks BH. Mammary gigantism and D-penicillamine. Clin Endocrinol (Oxf). 1984;21:219-22.
93. Passas C, Weinstein A. Breast gigantism with penicillamine therapy. Arthritis Rheum. 1978;21:167-8.
94. De Castro CC. Subcutaneous mastectomy for gigantomastia in an adolescent girl. Case report. Plast Reconstr Surg. 1977;59:575-8.
95. Greeley PW, Robertson LE, Curtin JW. Mastoplasty for massive bilateral benign breast hypertrophy associated with pregnancy: case report. Ann Surg. 1965;162:1081-3.
96. Boyce SW, Hoffman PG, Jr., Mathes SJ. Recurrent macromastia after subcutaneous mastectomy. Ann Plast Surg. 1984;13:511-8.
97. Sheehan HL. Pituitary necrosis. Br Med Bull. 1968;24:59-70.
98. Sheehan HL. Atypical hypopituitarism. Proc R Soc Med. 1961;54:43-48.
99. Kauppila A, Chatelain P, Kirkinen P, Kivinen S, Ruokonen A. Isolated prolactin deficiency in a woman with puerperal alactogenesis. J Clin Endocrinol Metab. 1987;64:309-12.
100. Pfaffle RW, Otten B, Eiholzer U, Kim C, Blankenstein O. A genetic cause of familial and sporadic cases with combined pituitary hormone deficiencies for GH, Prl, and TSH. Hormone Research. 1995;44:9.
101. de Zegher F, Pernasetti F, Vanhole C, Devlieger H, Van den Berghe G, Martial JA. The prenatal role of thyroid hormone evidenced by fetomaternal Pit-1 deficiency. J Clin Endocrinol Metab. 1995;80:3127-30.
102. Nishimori K, Young LJ, Guo Q, Wang Z, Insel TR, Matzuk MM. Oxytocin is required for nursing but is not essential for parturition or reproductive behavior. Proc Natl Acad Sci U S A. 1996;93:11699-704.
103. Sharp EA. Historical review of a syndrome embracing utero-ovarian atrophy with persistent lactation. American Journal of Obstetrics and Gynecology. 1935;30:411-414.
104. Boyd AE, 3rd, Reichlin S, Turksoy RN. Galactorrhea-amenorrhea syndrome: diagnosis and therapy. Ann Intern Med. 1977;87:165-75.
105. Tolis G, Somma M, Van Campenhout J, Friesen H. Prolactin secretion in sixty-five patients with galactorrhea. Am J Obstet Gynecol. 1974;118:91-101.
106. Gomez F, Reyes FI, Faiman C. Nonpuerperal galactorrhea and hyperprolactinemia. Clinical findings, endocrine features and therapeutic responses in 56 cases. Am J Med. 1977;62:648-60.
107. Kleinberg DL, Noel GL, Frantz AG. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N Engl J Med. 1977;296:589-600.
108. Yazigi RA, Quintero CH, Salameh WA. Prolactin disorders. Fertil Steril. 1997;67:215-25.
109. Biller BM, Luciano A, Crosignani PG, et al. Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med. 1999;44:1075-84.
110. Antunes JL, Housepian EM, Frantz AG, et al. Prolactin-secreting pituitary tumors. Annals of Neurology. 1977;2:148-153.
111. Kleinberg DL, Todd J. Evidence that human growth hormone is a potent lactogen in primates. J Clin Endocrinol Metab. 1980;51:1009-13.
112. Martin TL, Kim M, Malarkey WB. The natural history of idiopathic hyperprolactinemia. J Clin Endocrinol Metab. 1985;60:855-8.
113. Webb CB, Thominet JL, Barowsky H, Berelowitz M, Frohman LA. Evidence for lactotroph dopamine resistance in idiopathic hyperprolactinemia. J Clin Endocrinol Metab. 1983;56:1089-93.
114. Falaschi P, del Pozo E, Rocco A, et al. Prolactin release in polycystic ovary. Obstet Gynecol. 1980;55:579-82.
115. Falaschi P, Rocco A, del Pozo E. Inhibitory effect of bromocriptine treatment on luteinizing hormone secretion in polycystic ovary syndrome. J Clin Endocrinol Metab. 1986;62:348-51.
116. Lavric MV. Galactorrhea and amenorrhea with polycystic ovaries. Del Castillo syndrome or polycystic ovarian syndrome. Am J Obstet Gynecol. 1969;104:814-7.
117. Rosen SW, Weintraub BD, Aaronson SA. Nonrandom ectopic protein production by malignant cells: direct evidence in vitro. J Clin Endocrinol Metab. 1980;50:834-41.
118. Rees LH. The biosynthesis of hormones by non-endocrine tumours--a review. J Endocrinol. 1975;67:143-75.
119. Turkington RW. Ectopic production of prolactin. N Engl J Med. 1971;285:1455-8.
120. Hatfill SJ, Kirby R, Hanley M, Rybicki E, Bohm L. Hyperprolactinemia in acute myeloid leukemia and indication of ectopic expression of human prolactin in blast cells of a patient of subtype M4. Leuk Res. 1990;14:57-62.
121. Arbaiza D, Noriega K, Marcial J, Wachtel A, Perez C, Torres CF. Ectopic production of prolactin in an infant with non-Hodgkin lymphoma. Med Pediatr Oncol. 1999;32:311-2.
122. Ales N, Flynn J, Byrd JC. Novel presentation of acute myelogenous leukemia as symptomatic galactorrhea. Ann Intern Med. 2001;135:303-4.
123. Pellegrini I, Lebrun JJ, Ali S, Kelly PA. Expression of prolactin and its receptor in human lymphoid cells. Mol Endocrinol. 1992;6:1023-31.
124. Noel GL, Suh HK, Stone JG, Frantz AG. Human prolactin and growth hormone release during surgery and other conditions of stress. J Clin Endocrinol Metab. 1972;35:840-51.
125. MacFarlane IA, Rosin MD. Galactorrhoea following surgical procedures to the chest wall: the role of prolactin. Postgrad Med J. 1980;56:23-5.
126. Morley JE, Dawson M, Hodgkinson H, Kalk WJ. Galactorrhea and hyperprolactinemia associated with chest wall injury. J Clin Endocrinol Metab. 1977;45:931-5.
127. Van Wyk JJ, Grumbach MM. Syndrome of precocious menstruation and galactorrhea in juvenile hypothyroidism: an example of hormonal overlap in pituitary feedback. Journal of Pediatrics. 1960;57:416-435.
128. Kapcala LP. Galactorrhea and thyrotoxicosis. Arch Intern Med. 1984;144:2349-50.
129. Cromwell P, Anyan W. Depot medroxyprogesterone acetate galactorrhea. J Adolesc Health. 1998;23:61.
130. Windgassen K, Wesselmann U, Schulze Monking H. Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology. Neuropsychobiology. 1996;33:142-6.
131. Pena KS, Rosenfeld JA. Evaluation and treatment of galactorrhea. Am Fam Physician. 2001;63:1763-70.
132. Rains CP, Bryson HM, Fitton A. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Drugs. 1995;49:255-79.